“Future in vivo immune cell engineering platforms will deliver not just CAR constructs but additional genetic modifications and programming tailored to enhance potency and safety in the target indication.” Yu (Clay) Cao, Vice President, Global Head of Drug Discovery, GenEditBio and Guest Editor of Cell & Gene Therapy Insights’ February edition speaks with Shon Green, Cofounder and CSO, Zelig Therapeutics Inc. In vivo CAR-T therapies promise to revolutionize cell and gene therapy by engineering T cells directly within the body, eliminating the need for labor-intensive and costly ex vivo manufacturing. This innovation brings new scientific, operational, and regulatory challenges. In this in-depth interview, Dr Shon Green, a leading scientist and biotechnology executive, shares her perspective on preclinical modeling, first-in-human dosing strategies, CMC hurdles, new therapeutic opportunities, and the evolving global development landscape.
Shon Green (Fri,) studied this question.